Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on EchoHealthy Individuals With no Cardiopulmonary Disease
Trial Locations (1)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER